ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 8

Emerging Therapies in RCC: Shaping Future Treatment Sequences

March 21, 2025

Pedro C. Barata, MD, MSc, FACP , Moshe Ornstein, MD, Elizabeth Wulff-Burchfield, MD , Kathryn E. Beckermann, MD, PhD

Experts discuss the role of belzutifan and tivozanib in the treatment paradigm for advanced renal cell carcinoma (RCC), including key findings from the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.

EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

EP. 3: Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC

EP. 4: RCC Treatment Selection: Expert Perspectives on Long-Term Data and Insights on Treatment Selection

EP. 5: Optimizing IO/TKI Success: Managing Adverse Effects and Personalizing Treatment

EP. 6: Navigating RCC Progression: Optimizing Treatment Sequence After the First Line

EP. 7: Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies

Now Viewing

EP. 8: Emerging Therapies in RCC: Shaping Future Treatment Sequences

EP. 9: RCC Treatment Evolution: Expert Perspectives on the Evolving Landscape and Advances From ASCO GU 2025

Video content above is prompted by the following:

With belzutifan and tivozanib gaining traction in advanced RCC, how do you see these agents fitting into the treatment paradigm?
Please briefly highlight the phase 3 LITESPARK-005 trial investigating belzutifan vs everolimus in previously treated advanced RCC patients.